Twist Bioscience (TWST)
(Delayed Data from NSDQ)
$31.54 USD
+0.46 (1.48%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $31.53 -0.01 (-0.03%) 7:20 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
TWST 31.54 +0.46(1.48%)
Will TWST be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for TWST based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TWST
Twist Bioscience (TWST) Soars 12.5%: Is Further Upside Left in the Stock?
5 Best Performing Stocks of the Top ETF of November
TWST: What are Zacks experts saying now?
Zacks Private Portfolio Services
Twist Bioscience (TWST) Reports Q4 Loss, Tops Revenue Estimates
Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates
Bayer (BAYRY) Partners Twist Bioscience for Drug Discovery
Other News for TWST
First Week of June 21st Options Trading For Twist Bioscience (TWST)
Twist Bioscience to Report Fiscal 2024 Second Quarter Financial Results on Thursday, May 2, 2024
Cathie Wood's ARK Investment bought 133K shares of Twist Bioscience today
Twist Bioscience price target lowered by $5 at Barclays, here's why
Analyst Scoreboard: 5 Ratings For Twist Bioscience